Biotinidase deficiency due to a de novo mutation or gonadal mosaicism in a first child

Rodolfo Tonin, Anna Caciotti, Silvia Funghini, Giancarlo la Marca, Elisabetta Pasquini, Erica Cayton, Sean D. Mooney, Renzo Guerrini, Amelia Morrone

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Biotinidase deficiency (BD), which is caused by BTD genetic lesions, if untreated, can result in neurological and cutaneous manifestations. Biotin supplementation can improve or prevent symptoms.We herewith present a family, which we studied at biochemical and molecular level, after identifying the proband through a newborn screening programme. BTD gene molecular analysis showed the proband to be compound heterozygous for the c.1330. G. > C p.(Asp444His) mild known variant, and for the c.1475 C. > T p.(Thr492Ile) new variant. Bioinformatic analysis allowed us to confirm the pathogenic role of the newly identified variant.The proband's father, who exhibited low biotinidase (BTD) enzyme activity, was homozygous for the mild variant, whereas the proband's mother, who exhibited borderline BTD values, the BTD mutation carrier status could not be detected.This is the first description of a patient with BD harbouring a variant whose origin is either de novo or the consequence of gonadal mosaicism.BTD molecular analysis and bioinformatic tools for the evaluation of pathogenicity of newly identified variants are necessary for diagnostic purposes (i.e., clarifying borderline enzyme assays and the carrier status of parents), and for genetic counselling.

Original languageEnglish
Pages (from-to)70-72
Number of pages3
JournalClinica Chimica Acta
Volume445
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Biotinidase
Biotinidase Deficiency
Mosaicism
Mutation
Computational Biology
Bioinformatics
Skin Manifestations
Genetic Counseling
Enzyme Assays
Biotin
Neurologic Manifestations
Fathers
Virulence
Enzyme activity
Parents
Mothers
Newborn Infant
Assays
Screening
Genes

Keywords

  • Bioinformatic prediction tools
  • Biotinidase deficiency
  • BTD
  • De novo mutation
  • Unusual biochemical-molecular correlation

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical
  • Medicine(all)

Cite this

Tonin, R., Caciotti, A., Funghini, S., la Marca, G., Pasquini, E., Cayton, E., ... Morrone, A. (2015). Biotinidase deficiency due to a de novo mutation or gonadal mosaicism in a first child. Clinica Chimica Acta, 445, 70-72. https://doi.org/10.1016/j.cca.2015.03.010

Biotinidase deficiency due to a de novo mutation or gonadal mosaicism in a first child. / Tonin, Rodolfo; Caciotti, Anna; Funghini, Silvia; la Marca, Giancarlo; Pasquini, Elisabetta; Cayton, Erica; Mooney, Sean D.; Guerrini, Renzo; Morrone, Amelia.

In: Clinica Chimica Acta, Vol. 445, 01.05.2015, p. 70-72.

Research output: Contribution to journalArticle

Tonin, R, Caciotti, A, Funghini, S, la Marca, G, Pasquini, E, Cayton, E, Mooney, SD, Guerrini, R & Morrone, A 2015, 'Biotinidase deficiency due to a de novo mutation or gonadal mosaicism in a first child', Clinica Chimica Acta, vol. 445, pp. 70-72. https://doi.org/10.1016/j.cca.2015.03.010
Tonin R, Caciotti A, Funghini S, la Marca G, Pasquini E, Cayton E et al. Biotinidase deficiency due to a de novo mutation or gonadal mosaicism in a first child. Clinica Chimica Acta. 2015 May 1;445:70-72. https://doi.org/10.1016/j.cca.2015.03.010
Tonin, Rodolfo ; Caciotti, Anna ; Funghini, Silvia ; la Marca, Giancarlo ; Pasquini, Elisabetta ; Cayton, Erica ; Mooney, Sean D. ; Guerrini, Renzo ; Morrone, Amelia. / Biotinidase deficiency due to a de novo mutation or gonadal mosaicism in a first child. In: Clinica Chimica Acta. 2015 ; Vol. 445. pp. 70-72.
@article{6ce657f08be94391803ed33f60f792a5,
title = "Biotinidase deficiency due to a de novo mutation or gonadal mosaicism in a first child",
abstract = "Biotinidase deficiency (BD), which is caused by BTD genetic lesions, if untreated, can result in neurological and cutaneous manifestations. Biotin supplementation can improve or prevent symptoms.We herewith present a family, which we studied at biochemical and molecular level, after identifying the proband through a newborn screening programme. BTD gene molecular analysis showed the proband to be compound heterozygous for the c.1330. G. > C p.(Asp444His) mild known variant, and for the c.1475 C. > T p.(Thr492Ile) new variant. Bioinformatic analysis allowed us to confirm the pathogenic role of the newly identified variant.The proband's father, who exhibited low biotinidase (BTD) enzyme activity, was homozygous for the mild variant, whereas the proband's mother, who exhibited borderline BTD values, the BTD mutation carrier status could not be detected.This is the first description of a patient with BD harbouring a variant whose origin is either de novo or the consequence of gonadal mosaicism.BTD molecular analysis and bioinformatic tools for the evaluation of pathogenicity of newly identified variants are necessary for diagnostic purposes (i.e., clarifying borderline enzyme assays and the carrier status of parents), and for genetic counselling.",
keywords = "Bioinformatic prediction tools, Biotinidase deficiency, BTD, De novo mutation, Unusual biochemical-molecular correlation",
author = "Rodolfo Tonin and Anna Caciotti and Silvia Funghini and {la Marca}, Giancarlo and Elisabetta Pasquini and Erica Cayton and Mooney, {Sean D.} and Renzo Guerrini and Amelia Morrone",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.cca.2015.03.010",
language = "English",
volume = "445",
pages = "70--72",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Biotinidase deficiency due to a de novo mutation or gonadal mosaicism in a first child

AU - Tonin, Rodolfo

AU - Caciotti, Anna

AU - Funghini, Silvia

AU - la Marca, Giancarlo

AU - Pasquini, Elisabetta

AU - Cayton, Erica

AU - Mooney, Sean D.

AU - Guerrini, Renzo

AU - Morrone, Amelia

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Biotinidase deficiency (BD), which is caused by BTD genetic lesions, if untreated, can result in neurological and cutaneous manifestations. Biotin supplementation can improve or prevent symptoms.We herewith present a family, which we studied at biochemical and molecular level, after identifying the proband through a newborn screening programme. BTD gene molecular analysis showed the proband to be compound heterozygous for the c.1330. G. > C p.(Asp444His) mild known variant, and for the c.1475 C. > T p.(Thr492Ile) new variant. Bioinformatic analysis allowed us to confirm the pathogenic role of the newly identified variant.The proband's father, who exhibited low biotinidase (BTD) enzyme activity, was homozygous for the mild variant, whereas the proband's mother, who exhibited borderline BTD values, the BTD mutation carrier status could not be detected.This is the first description of a patient with BD harbouring a variant whose origin is either de novo or the consequence of gonadal mosaicism.BTD molecular analysis and bioinformatic tools for the evaluation of pathogenicity of newly identified variants are necessary for diagnostic purposes (i.e., clarifying borderline enzyme assays and the carrier status of parents), and for genetic counselling.

AB - Biotinidase deficiency (BD), which is caused by BTD genetic lesions, if untreated, can result in neurological and cutaneous manifestations. Biotin supplementation can improve or prevent symptoms.We herewith present a family, which we studied at biochemical and molecular level, after identifying the proband through a newborn screening programme. BTD gene molecular analysis showed the proband to be compound heterozygous for the c.1330. G. > C p.(Asp444His) mild known variant, and for the c.1475 C. > T p.(Thr492Ile) new variant. Bioinformatic analysis allowed us to confirm the pathogenic role of the newly identified variant.The proband's father, who exhibited low biotinidase (BTD) enzyme activity, was homozygous for the mild variant, whereas the proband's mother, who exhibited borderline BTD values, the BTD mutation carrier status could not be detected.This is the first description of a patient with BD harbouring a variant whose origin is either de novo or the consequence of gonadal mosaicism.BTD molecular analysis and bioinformatic tools for the evaluation of pathogenicity of newly identified variants are necessary for diagnostic purposes (i.e., clarifying borderline enzyme assays and the carrier status of parents), and for genetic counselling.

KW - Bioinformatic prediction tools

KW - Biotinidase deficiency

KW - BTD

KW - De novo mutation

KW - Unusual biochemical-molecular correlation

UR - http://www.scopus.com/inward/record.url?scp=84925424576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925424576&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2015.03.010

DO - 10.1016/j.cca.2015.03.010

M3 - Article

VL - 445

SP - 70

EP - 72

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -